Blog Archives

Novo Nordisk (NVO-$76, NYSE) Reports Semaglutide Results for Weight Loss. The Next Megablockbuster?

https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data https://www.clinicaltrialsarena.com/news/novo-nordisk-semaglutide-weight/ Presently, Novo Nordisk estimates that fewer than 65 million people globally, of the total assumed sample of 650 million persons that are non diabetic and have an estimated 30+ BMI (body mass index) are utilizing any sort of

Posted in Portfolio Model Subscription

Grupo Aeroporturio Del Sureste (ASR-$175, NYSE): Portfolio Weighting Increased.

Posted in Portfolio Model Subscription

Astra-Zeneca Oxford Covid-19 Vaccine Study Determines the Product is Ineffective on South African Variant.

https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36?shareType=nongift The drill-down is worse than the top-line news. With an average age of 31 for the test pool; just how many at age 31 wind up hospitalized as a result of Covid-19 contraction (yes, blah, blah, blah, there is

Posted in Portfolio Model Subscription

Government of Canada Enters into a Manufacturing Production Agreement “Memorandum of Understanding” with Novavax (NVAX-$264, NASDAQ).

“That was a Shrewdly Negotiated Deal on behalf of the Government of Canada”….Said no one, Ever. The US public is often critical of the American federal and state response to the Covid-19 pandemic. In comparison to the actions undertaken by

Posted in Portfolio Model Subscription

Novavax (NVAX-$220.84, NASDAQ) Acquired for the Model Portfolio.

As a collector, it occasionally pains me to consider parting with an item. Sometimes, the thought process involved produces a dull, persistent headache until a decision is made. Conversely, when a recently discovered, newly authenticated, Caravaggio comes up for auction

Posted in Portfolio Model Subscription
Recent Comments
    Archives